Association of pigment epithelium derived factor with von Willebrand factor and plasminogen activator inhibitor 1 in patients with type 2 diabetes
Language English Country Czech Republic Media print-electronic
Document type Journal Article
PubMed
30904010
DOI
10.33549/physiolres.934013
PII: 934013
Knihovny.cz E-resources
- MeSH
- Biomarkers blood MeSH
- Diabetes Mellitus, Type 2 blood diagnosis MeSH
- Adult MeSH
- Plasminogen Activator Inhibitor 1 blood MeSH
- Insulin Resistance physiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Nerve Growth Factors blood MeSH
- Eye Proteins blood MeSH
- Cross-Sectional Studies MeSH
- Aged MeSH
- Serpins blood MeSH
- von Willebrand Factor metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Biomarkers MeSH
- Plasminogen Activator Inhibitor 1 MeSH
- Nerve Growth Factors MeSH
- Eye Proteins MeSH
- pigment epithelium-derived factor MeSH Browser
- SERPINE1 protein, human MeSH Browser
- Serpins MeSH
- von Willebrand Factor MeSH
To compare circulating pigment epithelium derived factor (PEDF) levels in type 2 diabetes patients (T2D) with and without metabolic syndrome (MetS+/-) to healthy controls and assess PEDF association with plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF) as markers of endothelial dysfunction. Fifty T2D individuals and forty healthy controls were included. PEDF, PAI-1, vWF, anthropological parameters, lipids, and markers of insulin resistance were investigated in all subjects. Compared to controls only MetS+ diabetics had higher PEDF levels [14.2 (10.2-16.0) mg/l vs. 11.1 (8.6-14.4) mg/l; p<0.05]. PEDF significantly correlated: positively with body mass index (rho=0.25), smoking (rho=0.21), C-reactive protein (rho=0.22), triglycerides (rho=0.38), non-HDL-cholesterol (rho=0.39), apolipoprotein B (rho=0.38), fasting glucose (rho=0.22), glycated hemoglobin (rho=0.24), C-peptide (rho=0.28), insulin (rho=0.26); and negatively with HDL-cholesterol (rho=-0.42) and apolipoprotein A1 (rho=-0.27). Independent association of PEDF with vWF in T2DMetS- subjects was found. Significantly elevated PEDF in T2DMet+ patients and its association with adverse metabolic profile confirmed PEDF as a marker of insulin resistance. Negative independent association of PEDF with vWF in T2DMetS- patients may reveal its angio-protective role.
References provided by Crossref.org